#IACH2024: Lymphoma and chronic lymphocytic leukemia

To update you on the exciting content presented at the 7th Annual Meeting of the International Academy of Clinical Hematology (IACH), we have collated our social media coverage. Catch up with our posts relating to lymphoma and chronic lymphocytic leukemia below.

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Amer Beitinjaneh @abeitin @univmiami @SylvesterCancer discusses the management of patients with R/R mantle cell lymphoma.
They highlight the role of BTK inhibitors, CAR T-cell therapies, transplantation, and novel therapies in the R/R… pic.twitter.com/xgqb7hKy33

— Lymphoma Hub (@lymphomahub) September 21, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Madiha Iqbal @MadihaIqbal13 @MayoClinic provides an update on the first-line management of patients with mantle cell lymphoma
They discuss the optimization of chemoimmunotherapy, the use of targeted agents such as BTK inhibitors, the… pic.twitter.com/RiVOSWzgDB

— Lymphoma Hub (@lymphomahub) September 21, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Christiane Pott, @UKSH_KI_HL, shares insights on MRD assessment in mantle cell #lymphoma. They discuss a treatment approach that involves identifying high-risk gene signatures, making early treatment adjustments, and determining which… pic.twitter.com/wqvAL84TXT

— Lymphoma Hub (@lymphomahub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | POSTER
Tamar Tadmor @TadmorTamar Bnai Zion Medical Center, presents an overview of the phase III BELLWAVE-011 trial.
The BELLWAVE-011 trial will assess the safety and efficacy of nemtabrutinib vs investigator’s choice of ibrutinib or acalabrutinib… pic.twitter.com/rPbIbffxk3

— Lymphoma Hub (@lymphomahub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | POSTER
Vasile Musteata, N. Testemitanu State University of Medicine and Pharmacy, shares findings from a single-center analysis of the outcomes of patients with Hodgkin lymphoma treated with combined chemotherapy.
The complete response and partial… pic.twitter.com/00FJFqzEkq

— Lymphoma Hub (@lymphomahub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | POSTER
Vasile Musteata, N. Testemitanu State University of Medicine and Pharmacy, presents results from an analysis of 84 patients with generalized nodal NHL.
70% of patients achieved a complete response following treatment with immunochemotherapy… pic.twitter.com/KmBbeUqvby

— Lymphoma Hub (@lymphomahub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Olivier Tournilhac @CHUClermontFd provides an overview of transplantation and cellular therapies in patients with CLL.
They discuss the use of transplantation and CAR T-cell therapies in patients with CLL, particularly in BTKi/BCL2i… pic.twitter.com/C6adFDF3uZ

— Lymphoma Hub (@lymphomahub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Farrukh Awan @awandoc @UTSWMedCenter discusses first-line therapy in patients with CLL.
They highlight the role of BTK inhibitors, anti-CD20 antibodies, BCL2 inhibitors, and potential combination therapies in patients with CLL, and… pic.twitter.com/6Q9F56MIuT

— Lymphoma Hub (@lymphomahub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Andrew Davies @AndyD1036 @UHSFT shares insights on bispecific antibodies in patients with DLBCL.
They highlight key clinical trial data and discuss potential advantages over CAR T-cell therapies.
Follow our live feed for more updates:… pic.twitter.com/MgQusxxpgm

— Lymphoma Hub (@lymphomahub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Mariana Bastos-Oreiro @DrBastosOreiroM Gregorio Marañón Hospital, Madrid, provides an overview of CAR T-cell therapies for patients with DLBCL.
They discuss efficacy and safety results from clinical trials and real-world studies, and… pic.twitter.com/1fWBaxWpvk

— Lymphoma Hub (@lymphomahub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Andrew Davies @AndyD1036 @UHSFT discusses first-line treatment in patients with DLBCL.
They highlight advancements in disease classification and the evolving role of therapies targeting cell surface markers.
Follow our live feed for… pic.twitter.com/5gEO6lz2UX

— Lymphoma Hub (@lymphomahub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Nilanjan Ghosh @NGhoshMD @LevineCancer provides an overview of salvage therapy in patients with R/R Hodgkin lymphoma.
They discuss salvage therapy options, and highlight some of the key considerations for treatment selection in this… pic.twitter.com/2qsHYwcmFw

— Lymphoma Hub (@lymphomahub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Graham Collins @graham74GC @OUHospitals @OxfordCancer examines first-line treatment in older/unfit patients with Hodgkin lymphoma.
They highlight some of the key challenges and considerations, and discuss a potential treatment… pic.twitter.com/EglAs1T4qb

— Lymphoma Hub (@lymphomahub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Farrukh Awan @awandoc @UTSWMedCenter discusses first-line treatment in young/fit patients with Hodgkin lymphoma (HL).
They provide an overview of treatment options for patients with advanced-stage and early-stage HL, and highlight key… pic.twitter.com/vTDjiZZOpB

— Lymphoma Hub (@lymphomahub) September 19, 2024

CONGRESS #EHA2024 | Poster | Jan Burger @MDAndersonNews reports phase 2 study of time-limited treatment with acalabrutinib plus obinutuzumab in pts with treatment-naïve CLL. N=28, estimated 2 yr PFS & OS were 95.8%. ORR=100%, CR=67%, PR=33% at end of therapy. BM infiltration by… pic.twitter.com/hBJiEE4ELA

— Lymphoma Hub (@lymphomahub) June 15, 2024